Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

SAB Biotherapeutics (SABS) Equity Ratio (2020 - 2025)

Historic Equity Ratio for SAB Biotherapeutics (SABS) over the last 6 years, with Q3 2025 value amounting to 0.9.

  • SAB Biotherapeutics' Equity Ratio rose 3118.01% to 0.9 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.9, marking a year-over-year increase of 3118.01%. This contributed to the annual value of 0.59 for FY2024, which is 1391.8% down from last year.
  • As of Q3 2025, SAB Biotherapeutics' Equity Ratio stood at 0.9, which was up 3118.01% from 0.4 recorded in Q2 2025.
  • SAB Biotherapeutics' 5-year Equity Ratio high stood at 0.9 for Q3 2025, and its period low was 0.3 during Q3 2021.
  • Its 5-year average for Equity Ratio is 0.57, with a median of 0.58 in 2022.
  • In the last 5 years, SAB Biotherapeutics' Equity Ratio skyrocketed by 9441.02% in 2022 and then crashed by 4647.92% in 2025.
  • Quarter analysis of 5 years shows SAB Biotherapeutics' Equity Ratio stood at 0.48 in 2021, then increased by 28.42% to 0.61 in 2022, then rose by 11.88% to 0.68 in 2023, then dropped by 13.92% to 0.59 in 2024, then skyrocketed by 53.14% to 0.9 in 2025.
  • Its Equity Ratio was 0.9 in Q3 2025, compared to 0.4 in Q2 2025 and 0.56 in Q1 2025.